Metamizole sodium is a pharma-grade active pharmaceutical ingredient of the pyrazolone class, supplied as the monohydrate sodium salt of [(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)methylamino]methanesulfonic acid. The monohydrate has the molecular formula C₁₃H₁₆N₃NaO₄S·H₂O, molecular weight 333.34 g/mol, CAS registration 5907-38-0, and theoretical water content 5.4% by mass; the anhydrous entity is registered as CAS 68-89-3 with molecular weight 315.32 g/mol. The material is specified as a white to almost white crystalline powder and is freely soluble in water, which permits direct preparation of aqueous granulating fluids and concentrated injectable solutions without cosolvents. Routine industrial use covers film-coated tablets, uncoated tablets, hard-gelatin capsules, granule-filled sachets, dry syrups, oral solutions, and injectable ampoules or vials. Two route-specific models are supplied: a solid-oral grade controlled mainly for particle-size distribution, water content, and residual solvents; and a parenteral grade additionally controlled for bioburden, bacterial endotoxins, and insoluble particulate matter after dissolution. The active entity is a prodrug that is converted to 4-methylaminoantipyrine and 4-aminoantipyrine; these metabolites account for antipyretic and analgesic action but are not shared with non-pyrazolone non-opioid analgesics.

The powder form is hygroscopic and oxygen-sensitive under humid and illuminated conditions. Packaging in double polyethylene liners inside an aluminium-foil laminate with nitrogen overlay is specified for both grades to limit water uptake and oxidative discolouration. Open processing in areas above 60% relative humidity is to be avoided because surface sorption creates interstitial liquid bridges and reduces flowability.

Pharmacopoeial Specification Framework and Release Controls

Release testing follows the current Ph.Eur. monograph for metamizole sodium and, where required, is cross-referenced to ICH Q3C for residual solvents and ICH Q3D for elemental impurities. Identification is established by infrared absorption spectrophotometry and sodium reaction; assay on the dried basis is controlled to not less than 99.0% and not more than 101.0%. Related substances are determined by liquid chromatography under Ph.Eur. 2.2.29; the primary degradation product 4-methylaminoantipyrine is specifically limited, and total impurities are controlled by the pharmacopoeial threshold. Loss on drying at 105°C under Ph.Eur. 2.2.32 is typically 4.5–5.5% for the monohydrate, and water determination by Karl Fischer under Ph.Eur. 2.5.12 may be used where dehydration and rehydration behaviour must be documented. Sulphated ash is measured under Ph.Eur. 2.4.14. For the parenteral grade, bacterial endotoxins are evaluated by Ph.Eur. 2.6.14, and sub-visible particulate contamination after dissolution is tested by Ph.Eur. 2.9.19.

For solid-oral grade lots, particle-size distribution is also monitored by laser diffraction under Ph.Eur. 2.9.31. Production lots with D10 below 30 µm and D90 above 450 µm show increased segregation tendency in low-dose direct blends. The span, defined as (D90 − D10)/D50, is maintained below 2.0 for solid-oral lots intended for dry blending. Batches outside this range are re-milled or dry-compacted before use. All measurements are performed after dispersion in a dry air stream, because wet dispersion can dissolve the drug and produce a non-representative size distribution.

For capsule filling, the same oral-grade lot can shift from free-flowing to cohesive as relative humidity rises above 45%. Bulk density commonly ranges from 0.40 g/cm³ to 0.60 g/cm³, and tapped density from 0.60 g/cm³ to 0.80 g/cm³; the resulting Hausner ratio of 1.30–1.60 indicates a cohesive-to-poor flow classification under Ph.Eur. 2.9.34. Dosing-disc and dosator machines require forced feeder or pin agitation for mass uniformity below ±3%. Pre-sieving through 600 µm mesh and maintaining the filling suite at ≤45% relative humidity reduce adhesion to tooling and gelatin shells.

Batch-to-batch variation in crystal habit or loss on drying affects tamping density and final capsule weight. A tighter water content at 4.5–5.0% is often requested for capsule grades because low moisture limits liquid bridging and electrostatic charging. If static charge persists, the addition of 0.5–1.0% sodium stearyl fumarate and 0.5–1.0% colloidal silicon dioxide is applied, but blend residence time must be limited to avoid over-lubrication and delayed dissolution of the freely soluble API.

When a High-Speed Tablet Press Encounters Metamizole Sodium with Poor Flow Function

Direct compression is technically feasible only when the API fraction is small, because the powder is not inherently free-flowing. Angle-of-repose values between 35° and 45° are common; the threshold for reliable gravity-fed die filling is generally below 30°. On a 45-station rotary tablet press running at turret speed above 25 rpm, die-fill variability can exceed 5% unless paddle feeders or forced feeders are used. Low-dose tablets of 10 mg or 25 mg are produced by ordered mixing with a fine direct-compression carrier, followed by dilution with coarse lactose or dicalcium phosphate dihydrate. The premixing step must be performed in low-humidity air, because moist API adheres to high-speed blender walls and forms aggregates that are not recovered by subsequent blending.

Compaction pressure above 150 MPa may induce capping or lamination if the monohydrate water content is below 4.5%, because over-dried particles are brittle. Lubrication with magnesium stearate at 0.5–1.0% w/w is used, but the lubricant must be added at the end of the blend; high-shear mixing of magnesium stearate for more than 5 min can form hydrophobic films on this freely soluble API and slow tablet dissolution. If relative humidity in the compression suite exceeds 60%, pre-drying in a vacuum dryer at 40–50°C for 6–12 h may be required; however, dehydration of the monohydrate lattice can raise hygroscopic rebound and increase ejection force.

Wet Granulation, Drying, and Discolouration Management in Solid Dosage Forms

Wet granulation is the preferred route when tablet loading exceeds 25% w/w or when dose uniformity across 500 mg to 1000 mg tablet strengths must be protected. The API dissolves partially during binder addition; the solute re-crystallizes on drying and forms bridges between undissolved particles, improving compactibility. High-shear granulation with impeller speed 200–400 rpm and chopper speed 1500 rpm is completed within 10 min after binder solution addition to limit localized dissolution and discolouration. The final granule moisture before drying is commonly 5–8%. Fluid-bed drying at inlet-air temperature 55–65°C to a loss on drying of 1.0–2.0% is typical; the residual water is not the monohydrate water but the process moisture assigned for compressibility. X-ray powder diffraction and differential scanning calorimetry are used to confirm that the monohydrate lattice has been restored during conditioning at 45–55% relative humidity before compression.

Uncoated tablets stored above 60% relative humidity can yellow or brown even when assay loss is small. This colour change is driven by oxidative degradation of the pyrazolone ring, and it is controlled by opaque or aluminium-aluminium blisters, low-moisture packaging with desiccant, and control of transition-metal contamination. Aqueous film coating must be performed at low spray rate and inlet temperature below 60°C to avoid overwetting the tablet surface and initiating reversible surface dissolution.

Granule-filled sachet manufacturing relies on fluid-bed drying to produce flowable and dispersible granules. A typical target in production is 80–90% of granules retained between 150 µm and 850 µm sieves, with fines below 75 µm limited to 5% or less. Filling is performed at relative humidity below 40%. The sachet laminate is specified with moisture vapour transmission rate below 0.5 g/(m²·24 h), because water ingress causes caking and discolouration. For dry syrup presentations, dispersible granules are produced by spray granulation with a povidone or maltodextrin binder; reconstitution in water immediately forms a solution of the drug, but chemical stability in the reconstituted state is limited and is managed by opaque containers and refrigeration in markets where such packaging is authorized.

What Limits Terminal Sterilization Options for Metamizole Sodium Injection?

Injectable formulations are typically prepared at 500 mg/mL in water for injection, yielding a 2 mL ampoule containing 1 g metamizole sodium. The active ingredient dissolves without cosolvents, so the process does not require pH-sensitive solubilizers or non-aqueous solvents. However, oxygen-sensitive degradation is the principal constraint on sterilization. Aqueous solutions sparged with nitrogen and filled under nitrogen headspace show reduced formation of 4-methylaminoantipyrine and coloured degradation products. Terminal moist-heat sterilization at 121°C for 15 min can be employed only when the formulation and primary package are oxygen-free; many industrial lines use aseptic filtration through a 0.22 µm membrane followed by aseptic filling to avoid thermal colour formation. Pre-filtration bioburden is typically controlled to ≤10 CFU/100 mL, and bacterial endotoxin acceptance is calculated from the maximum daily dose under Ph.Eur. 2.6.14 using water-for-injection with ≤0.25 EU/mL.

The final solution pH is adjusted to 5.0–7.0 with hydrochloric acid or sodium hydroxide; this window balances chemical stability and injectability. Primary packaging in Type I borosilicate glass ampoules or vials with halobutyl rubber stoppers, headspace oxygen below 2%, and storage below 25°C limits discolouration. Sub-visible particulate matter is controlled after sealing by Ph.Eur. 2.9.19. If terminal sterilization is used, the related-substances profile must be compared against the aseptic control; an increase in total degradation products above the pharmacopoeial threshold may trigger rejection even if assay remains within specification.

Comparative Differentiation Against Other Non-Opioid Analgesic APIs

Metamizole sodium differs from paracetamol, ibuprofen, and acetylsalicylic acid in water solubility, formulation capability, and safety restriction. The sulfonate salt is freely soluble above 100 mg/mL at 25°C, while paracetamol dissolves near 14 mg/mL, acetylsalicylic acid near 3 mg/mL, and ibuprofen below 0.1 mg/mL. The high solubility permits aqueous wet granulation of high-dose tablets and concentrated aqueous injection without amphiphilic solvents. It also implies that dissolution testing of the API-based tablet is not the rate-limiting quality risk; finished-product dissolution methods must nevertheless discriminate formulation over-granulation or lubricant blinding.

Mechanistically, metamizole sodium is a pyrazolone prodrug converted to 4-methylaminoantipyrine and 4-aminoantipyrine; the pyrazolone-derived spasmolytic component is absent from paracetamol, ibuprofen, and acetylsalicylic acid. The critical safety difference is the rare but serious risk of agranulocytosis, which leads to restricted indication and prescription status in several jurisdictions. Paracetamol is limited by dose-dependent hepatotoxicity, ibuprofen by gastrointestinal and renal toxicity, and acetylsalicylic acid by bleeding risk and Reye syndrome. The table summarizes route-relevant differences.